Insider · CIK 0002009713
Matthew Wein
officer
Files at MGX (Metagenomi, Inc.). First filing Jun 9, 2025, latest Sep 10, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $763 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MGX: Metagenomi, Inc.
MGXOct 9, 2026 · close 1.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Metagenomi, Inc. | $415 358 shares | -0% | - | |
| 30Weak | Metagenomi, Inc. | $348 199 shares | -1% | +37% from low-59% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | MGX Metagenomi, Inc. | SOpen-market sale Common Stock | -358 | $1.16 | $415 | 126,133 | 32 d ago |
| Jun 6, 2025 | MGX Metagenomi, Inc. | SOpen-market sale Common Stock | -199 | $1.75 | $348 | 16,693 | Jun 9, 2025 |
| Apr 1, 2025 | MGX Metagenomi, Inc. | AGrant or award Common Stock | +3,650 | $0.00 | $0 | 13,117 | Apr 3, 2025 |
| Apr 1, 2025 | MGX Metagenomi, Inc. | AGrant or award Common Stock | +3,775 | $0.00 | $0 | 16,892 | Apr 3, 2025 |
| Apr 1, 2025 | MGX Metagenomi, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,875 | $0.00 | $0 | 21,875 | Apr 3, 2025 |
| Apr 1, 2025 | MGX Metagenomi, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,725 | $0.00 | $0 | 22,725 | Apr 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.